Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Completed Not applicable Interventional

A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life

NCT05523180
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
ResBiotic Nutrition, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • The Villages, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 23, 2026, 1:14 PM EDT
Terminated No phase listed Interventional Results available

Determination of the Prevalence and Severity of Expiratory Flow Limitation in Chronic Obstructive Pulmonary Disease Patients

NCT03851510
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Noninvasive Ventilation
Interventions
Vector ventilator, Resmon Pro
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
40 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

NCT03250182
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT010
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional

A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.

NCT00274560
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
20
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00932646
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Placebo, Foradil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT05986591
View directory record Official record
Conditions
COPD
Interventions
Test Product - Tiotropium Bromide Inhalation Powder 18 mcg, Spiriva Handihaler (Tiotropium Bromide) 18 mcg, Placebo
Combination Product
Lead sponsor
Xiromed LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

NCT02207829
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

NCT02105961
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Riverside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 23, 2026, 1:14 PM EDT
Recruiting Phase 2 Interventional

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

NCT05237505
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Overlap Syndrome
Interventions
bi-level positive pressure non invasive ventilation, Oxygen gas
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 1:14 PM EDT
Terminated Phase 2 Interventional

Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease

NCT00181272
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 23, 2026, 1:14 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Thoracic Lymphatic Pump Techniques for Reducing Lung Volumes in Persons With Chronic Obstructive Pulmonary Disease

NCT02030145
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Compressive Thoracic Lymphatic Pump, Classic Thoracic Lymphatic Pump
Procedure
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 23, 2026, 1:14 PM EDT
Recruiting Phase 3 Interventional

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 23, 2026, 1:14 PM EDT
Not yet recruiting Not applicable Interventional

Developing an Intervention to Optimize Virtual Care Adoption for COPD Management

NCT05986214
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
VC-OPTIONS
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
2
States / cities
Bedford, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

NCT01862536
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tadalafil, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
West Los Angeles, California • Denver, Colorado • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 23, 2026, 1:14 PM EDT
Terminated Phase 3 Interventional Results available

Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02587351
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Metoprolol succinate, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 84 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 23, 2026, 1:14 PM EDT
Active, not recruiting No phase listed Observational

CareCOPD - COPD Home Monitoring Study

NCT04918095
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CareCOPD Platform
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
40 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

NCT03673670
View directory record Official record
Conditions
COPD
Interventions
RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Winter Park, Florida • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

NCT02085161
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Torrance, California • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 23, 2026, 1:14 PM EDT
Completed No phase listed Observational

Analyzing Lung Tissue in People With and Without Chronic Obstructive Pulmonary Disease Who Are Undergoing Lung Transplantation

NCT00756522
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
There is no intervention. Study is observational.
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional

BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)

NCT01551953
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tai chi, Mind-body breathing, Education
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 23, 2026, 1:14 PM EDT
Completed No phase listed Observational

Replication of the INSPIRE Trial in Healthcare Claims Data

NCT05179512
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Tiotropium, salmeterol-fluticasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
98,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional

Randomized Controlled Trial of Exercise Training in Patients With COPD

NCT00012792
View directory record Official record
Conditions
Lung Diseases, Obstructive
Interventions
Exercise Training
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 79 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 23, 2026, 1:14 PM EDT